Search Results - "Filderman, Jessica N"

Finding the right help in the tumor microenvironment by Filderman, Jessica N, Storkus, Walter J

“…Tumor-infiltrating lymphocytes (TILs) contain substantial numbers of CD4+ T cells mediating pro- and antitumor functions. While CD4+ Tregs are well…”
Get full text

STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development by Filderman, Jessica N., Appleman, Mark, Chelvanambi, Manoj, Taylor, Jennifer L., Storkus, Walter J.

“…Tertiary lymphoid structures (TLS), also known as ectopic lymphoid structures (ELS) or tertiary lymphoid organs (TLO), represent a unique subset of lymphoid…”
Get full text

Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists by Filderman, Jessica N, Taylor, Jennifer L, Wang, Jianmin, Zhang, Yali, Singh, Prashant, Ross, Mark A, Watkins, Simon C, Nedal Al Bzour, Ayah, Karapetyan, Lilit, Kalinski, Pawel, Storkus, Walter J

“…Stimulator of Interferon Genes (STING) is a dsDNA sensor that triggers type I inflammatory responses. Recent data from our group and others support the…”
Get full text

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma by Storkus, Walter J, Maurer, Deena, Lin, Yan, Ding, Fei, Bose, Anamika, Lowe, Devin, Rose, Amy, DeMark, Melissa, Karapetyan, Lilit, Taylor, Jennifer L, Chelvanambi, Manoj, Fecek, Ronald J, Filderman, Jessica N, Looney, Timothy J, Miller, Lauren, Linch, Elizabeth, Lowman, Geoffrey M, Kalinski, Pawel, Butterfield, Lisa H, Tarhini, Ahmad, Tawbi, Hussein, Kirkwood, John M

“…BackgroundA first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA)…”
Get full text

Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1 by Taylor, Jennifer L, Kokolus, Kathleen M, Basse, Per H, Filderman, Jessica N, Cosgrove, Chloe E, Watkins, Simon C, Gambotto, Andrea, Lowe, Devin B, Edwards, Robert P, Kalinski, Pawel, Storkus, Walter J

“…We previously reported that dendritic cell (DC)-based vaccines targeting antigens expressed by tumor-associated vascular endothelial cells (VECs) and pericytes…”
Get full text

STING Agonists as Cancer Therapeutics by Amouzegar, Afsaneh, Chelvanambi, Manoj, Filderman, Jessica N, Storkus, Walter J, Luke, Jason J

“…The interrogation of intrinsic and adaptive resistance to cancer immunotherapy has identified lack of antigen presentation and type I interferon signaling as…”
Get full text

Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes by Filderman, Jessica N, Luke, Jason J, Storkus, Walter J

Get full text

Neoepitopes as Difference Makers for General Cancer Vaccines? by Filderman, Jessica N, Storkus, Walter J

“…The cancer mutanome has been associated with disease prognosis as well as response to interventional immunotherapy and provides a substrate for development of…”
Get full text

Finding the right help in the tumor microenvironment by Filderman, Jessica N, Storkus, Walter J

“…Tumor-infiltrating lymphocytes (TILs) contain substantial numbers of CD4+ T cells mediating pro- and antitumor functions. While CD4+ Tregs are well…”
Get full text